SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study-Reference-Cited by-同舟云学术

SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study

Published:2022-11 Issue: Volume:22 Page:100502
ISSN:2666-7762
Container-title:The Lancet Regional Health - Europe
language:en
Short-container-title:The Lancet Regional Health - Europe

Author:

Frahm Niklas^ORCID,Fneish Firas,Ellenberger David,Haas Judith,Loebermann Micha,Parciak Tina,Peters Melanie,Pöhlau Dieter,Rodgers Jeff,Röper Anna-Lena,Schilling Sarah,Stahmann Alexander,Temmes Herbert,Zettl Uwe K.,Middleton Rodden M.

Publisher

Elsevier BV

Subject

Health Policy,Oncology,Internal Medicine

Reference39 articles.

1. Vaccination and multiple sclerosis in the era of the COVID-19 pandemic;Monschein;J Neurol Neurosurg Psychiatry,2021

2. World Health Organization. WHO coronavirus (COVID-19) dashboard. https://covid19.who.int. Accessed 13 July 2022

3. COVID-19 severity in multiple sclerosis: putting data into context;Sormani;Neurol Neuroimmunol Neuroinflammation,2022

4. Associations of DMT therapies with COVID-19 severity in multiple sclerosis;Simpson-Yap;Neurology,2021

5. Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus;Centonze;J Neurol,2021

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identifying and reducing risks of neurological complications associated with vaccination;Nature Reviews Neurology;2024-08-07

2. Management of patients with neurological diseases considering post‐pandemic coronavirus disease 2019 (COVID‐19) related risks and dangers — An updated European Academy of Neurology consensus statement;European Journal of Neurology;2024-08

3. Vaccination status and self-reported side effects after SARS-CoV-2 vaccination in relation to psychological and clinical variables in patients with multiple sclerosis;Scientific Reports;2024-05-28

4. Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab;JAMA Network Open;2024-04-12

5. Immunogenicity and safety of vaccines in multiple sclerosis: A systematic review and meta-analysis;Journal of the Neurological Sciences;2024-01